Brain Health

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the problems with approaching public health issues, such as mental health and substance use disorders, with an industrialized approach to problem solving.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.

Study indicates those who experienced a greater amount of stress from the COVID-19 pandemic had reduced information processing speed.

Investigators found that an additional hour of sleep correlated with a 26% decrease in an infant’s risk of being overweight.

Study results show that clonal hematopoiesis of indeterminate potential is associated with a lower likelihood of developing AD.

Although the test does not definitively diagnose problems such as Alzheimer disease, it helps physicians get a baseline of their patients’ cognitive functioning.

Study results show more activity in brain areas affecting sympathy and movement when the women viewed the photos.

Investigators focus on the relationship with neuron activity and find that sodium consumption plays a role.

The technique uses light and nanoparticles to temporarily open the tight junctions that protect the brain and allow medication to reach its target.

An embryonic stem cell model allowed investigators to study the genetic architecture first in hypothalamic progenitor cells, prior to their full development, and then nucleus-like hypothalamic neurons.

The researchers based this conclusion on the analysis of VZV-infected primary human brain vascular adventitial fibroblasts (HBVAFs), which are among the first arterial cells infected in VZV vasculopathy.

After adjusting for age, education level, and gender, each 1-point increase in dietary inflammatory score was linked to a 21% increase in cognitive impairment, study results show.

The report also describes the benefits of interventions at the family, individual, institutional, organizational, and policy levels and differentiates AD from other types of dementia.

It is an FDA-approved-agent agnostic approach to gathering routine clinical practice data and outcomes for sharing and transparency.

Study addresses the impact of COVID-19 on the mental health of older people.

The investigators found that older adults who studied Spanish had similar improvements to critical cognitive skills as those engaged in brain training activities specifically targeting those skills.

Results of a study by the American Heart Association show a genetic predisposition may lead to an association between sleeplessness and brain bleeding.

Proposed demonstration project could have a negative effect on people with certain conditions, such as stroke, traumatic brain injury, and spinal cord injury.

Study indicates that women with trauma had greater white matter hyperintensities (WMH) than women without trauma, and the most common trauma associated with WMH was sexual violence.

The mechanism of action of solriamfetol is mediated through its activity as a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Michael Frank, CEO of Revive Therapeutics, and Derrick Welsh, COO of Psilocin Pharma, a division of Revive Therapeutics, discuss clinical research investigating novel treatment targets for psilocybin, such as treatment-resistant depression in patients with cancer.

The paper reviews the safety profile of solriamfetol in treating ES associated with OSA or narcolepsy and discusses subject areas such as pharmacology, clinical efficacy, and tolerability of the drug.

The researchers also demonstrated that ketone supplements may be a novel therapy for protecting and improving brain health in people with obesity who are at risk of developing neurocognitive impairment.

In a study, individuals who were taking prucalopride had better memory tests and fMRI scans indicating enhanced brain activity in relation to cognition.

Symptoms of fibromyalgia often begin after an event, such as physical trauma, surgery, infection, or significant psychological stress.

Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.

Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.